DSDaniel E. Singer

Daniel E. Singer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel E. Singer has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Alan S. Go

    Department of Medicine, University of California San Francisco, San Francisco, CA

    8 shared publications
  • Margaret C. Fang

    Department of Medicine, University of California San Francisco, San Francisco, CA

    5 shared publications
  • Jonathan L. Halperin

    Mount Sinai Medical Center, The Cardiovascular Institute, New York, NY (J.L.H.).

    4 shared publications
  • Leila H. Borowsky

    Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA

    3 shared publications
  • Natalia Udaltsova

    Division of Research, Kaiser Permanente of Northern California, Oakland, CA

    3 shared publications
  • Niela K. Pomernacki

    Division of Research, Kaiser Permanente of Northern California, Oakland, CA

    3 shared publications

Latest Publications

  • Open Access

    Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial

    by Daniel E. Singer, Anne S. Hellkamp, Zhong Yuan, Yuliya Lokhnygina, Manesh R. Patel, Jonathan P. Piccini, Graeme J. Hankey, Günter Breithardt, Jonathan L. Halperin, Richard C. Becker, et al.

    Background: In the ROCKET AF (Rivaroxaban–Once‐daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial, marked regional differences in control of warfarin anticoagulation, measured as the average individual patient time in the therapeutic range ( iTTR ) of the international normalized ratio ( INR ), were associated with longer inter‐ INR test intervals. The standard R osendaal approach can produce biased low estimates of TTR after an appropriate dose change if the follow‐up INR test interval is prolonged. We explored the effect of alternative calculations of TTR that more immediately account for dose changes on regional differences in mean iTTR in the ROCKET AF trial. Methods and Results: We used an INR imputation method that accounts for dose change. We compared group mean iTTR values between our dose change–based method with the standard R osendaal method and determined that the differences between approaches depended on the balance of dose changes that produced in‐range INR s (“corrections”) versus INR s that were out of range in the opposite direction (“overshoots”). In ROCKET AF , the overall mean iTTR of 55.2% (Rosendaal) increased up to 3.1% by using the dose change–based approach, depending on assumptions. However, large inter‐regional differences in anticoagulation control persisted. Conclusions: TTR , the standard measure of control of warfarin anticoagulation, depends on imputing daily INR values for the vast majority of follow‐up days. Our TTR calculation method may better reflect the impact of warfarin dose changes than the Rosendaal approach. In the ROCKET AF trial, this dose change–based approach led to a modest increase in overall mean iTTR but did not materially affect the large inter‐regional differences previously reported. Clinical Trial Registration: URL: ClinicalTrials.gov. Unique identifier: NCT00403767.


  • Adding Rigor to Stroke Risk Prediction in Atrial Fibrillation

    by Daniel E. Singer, Michael D. Ezekowitz


  • Top Cited Papers
    Open Access

    A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score

    by Daniel E. Singer, Yuchiao Chang, Leila H. Borowsky, Margaret C. Fang, Niela K. Pomernacki, Natalia Udaltsova, Kristi Reynolds, Alan S. Go

    Background: More accurate and reliable stroke risk prediction tools are needed to optimize anticoagulation decision making in patients with atrial fibrillation ( AF ). We developed a new AF stroke prediction model using the original A nticoagulation and R isk F actors in A trial F ibrillation ( ATRIA ) AF cohort and externally validated the score in a separate, contemporary, community‐based inception AF cohort, ATRIA – C ardiovascular R esearch N etwork ( CVRN ) cohort. Methods and Results: The derivation ATRIA cohort consisted of 10 927 patients with nonvalvular AF contributing 32 609 person‐years off warfarin and 685 thromboembolic events ( TE s). The external validation ATRIA ‐ CVRN cohort included 25 306 AF patients contributing 26 263 person‐years off warfarin and 496 TE s. Cox models identified 8 variables, age, prior stroke, female sex, diabetes mellitus, heart failure, hypertension, proteinuria, and eGFR 2 or end‐stage renal disease, plus an age×prior stroke interaction term for the final model. Point scores were assigned proportional to model coefficients. The c‐index in the ATRIA cohort was 0.73 (95% CI , 0.71 to 0.75), increasing to 0.76 (95% CI , 0.74 to 0.79) when only severe events were considered. In the ATRIA ‐ CVRN , c‐indexes were 0.70 (95% CI , 0.67 to 0.72) and 0.75 (95% CI , 0.72 to 0.78) for all events and severe events, respectively. The C‐index was greater and net reclassification improvement positive comparing the ATRIA score with the CHADS 2 or CHA 2 DS 2 ‐VASc scores. Conclusions: The ATRIA stroke risk score performed better than existing risk scores, was validated successfully, and showed improvement in predicting severe events, which is of greatest concern. The ATRIA score should improve the antithrombotic decision for patients with AF and should provide a secure foundation for the addition of biomarkers in future prognostic models.


  • Open Access

    Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial

    by Daniel E. Singer, Anne S. Hellkamp, Jonathan P. Piccini, Kenneth W. Mahaffey, Yuliya Lokhnygina, Guohua Pan, Jonathan L. Halperin, Richard C. Becker, Günter Breithardt, Graeme J. Hankey, et al.

    Background: Vitamin K antagonist ( VKA ) therapy remains the most common method of stroke prevention in patients with atrial fibrillation. Time in therapeutic range ( TTR ) is a widely cited measure of the quality of VKA therapy. We sought to identify factors associated with TTR in a large, international clinical trial. Methods and Results: TTR (international normalized ratio [ INR ] 2.0 to 3.0) was determined using standard linear interpolation in patients randomized to warfarin in the ROCKET AF trial. Factors associated with TTR at the individual patient level (i‐ TTR ) were determined via multivariable linear regression. Among 6983 patients taking warfarin, recruited from 45 countries grouped into 7 regions, the mean i‐ TTR was 55.2% (SD 21.3%) and the median i‐ TTR was 57.9% (interquartile range 43.0% to 70.6%). The mean time with INR 3 was 15.7%. While multiple clinical features were associated with i‐ TTR , dominant determinants were previous warfarin use (mean i‐ TTR of 61.1% for warfarin‐experienced versus 47.4% in VKA ‐naïve patients) and geographic region where patients were managed (mean i‐ TTR varied from 64.1% to 35.9%). These effects persisted in multivariable analysis. Regions with the lowest i‐ TTR s had INR distributions shifted toward lower INR values and had longer inter‐ INR test intervals. Conclusions: Independent of patient clinical features, the regional location of medical care is a dominant determinant of variation in i‐ TTR in global studies of warfarin. Regional differences in mean i‐ TTR are heavily influenced by subtherapeutic INR values and are associated with reduced frequency of INR testing. Clinical Trial Registration: URL: ClinicalTrials.gov . Unique identifier: NCT 00403767.


  • Open Access

    Comparative effectiveness of post-discharge interventions for hospitalized smokers: study protocol for a randomized controlled trial

    by Sandra J Japuntich, Susan Regan, Joseph Viana, Justyna Tymoszczuk, Michele Reyen, Douglas E Levy, Daniel E Singer, Elyse R Park, Yuchiao Chang, Nancy A Rigotti

    Background: A hospital admission offers smokers an opportunity to quit. Smoking cessation counseling provided in the hospital is effective, but only if it continues for more than one month after discharge. Providing smoking cessation medication at discharge may add benefit to counseling. A major barrier to translating this research into clinical practice is sustaining treatment during the transition to outpatient care. An evidence-based, practical, cost-effective model that facilitates the continuation of tobacco treatment after discharge is needed. This paper describes the design of a comparative effectiveness trial testing a hospital-initiated intervention against standard care. Methods/design: A two-arm randomized controlled trial compares the effectiveness of standard post-discharge care with a multi-component smoking cessation intervention provided for three months after discharge. Current smokers admitted to Massachusetts General Hospital who receive bedside smoking cessation counseling, intend to quit after discharge and are willing to consider smoking cessation medication are eligible. Study participants are recruited following the hospital counseling visit and randomly assigned to receive Standard Care or Extended Care after hospital discharge. Standard Care includes a recommendation for a smoking cessation medication and information about community resources. Extended Care includes up to three months of free FDA-approved smoking cessation medication and five proactive computerized telephone calls that use interactive voice response technology to provide tailored motivational messages, offer additional live telephone counseling calls from a smoking cessation counselor, and facilitate medication refills. Outcomes are assessed at one, three, and six months after hospital discharge. The primary outcomes are self-reported and validated seven-day point prevalence tobacco abstinence at six months. Other outcomes include short-term and sustained smoking cessation, post-discharge utilization of smoking cessation treatment, hospital readmissions and emergency room visits, and program cost per quit. Discussion: This study tests a disseminable smoking intervention model for hospitalized smokers. If effective and widely adopted, it could help to reduce population smoking rates and thereby reduce tobacco-related mortality, morbidity, and health care costs. Trial registration: United States Clinical Trials Registry NCT01177176.


  • A New Era in Stroke Prevention for Atrial Fibrillation

    by Alan S. Go, Daniel E. Singer

    The article by Agarwal et al1 summarizing the performance of warfarin in recent trials of stroke prevention in atrial fibrillation (AF) in this issue of the Archives provides an opportunity to review the growing set of novel anticoagulation alternatives for patients with AF and the remaining role for warfarin. Atrial fibrillation, the most common significant cardiac arrhythmia, raises the risk of ischemic stroke 5-fold. Dose-adjusted warfarin therapy reduces this risk by two-thirds.2 However, warfarin therapy is burdensome and risky, and its effect varies as a result of food and drug interactions and genetic differences.3 The safe management of warfarin therapy demands frequent international normalized ratio (INR) testing and dose adjustment as well as ongoing patient education regarding common hazards. The risks of ischemic stroke and intracranial hemorrhage are minimized at INR values of 1.8 to 3.5.4 Beyond this range, the risks increase steeply.


  • CHA 2 DS 2 -VASc Risk Scheme

    by Daniel E. Singer, Margaret C. Fang, Alan S. Go


  • Response to Letter by Willey

    by Paul D. Ziegler, Taya V. Glotzer, Emile G. Daoud, D. George Wyse, Daniel E. Singer, Michael D. Ezekowitz

  • Top Cited Papers

    The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation

    by Daniel E. Singer, Yuchiao Chang, Margaret C. Fang, Leila H. Borowsky, Niela K. Pomernacki, Natalia Udaltsova, Alan S. Go

    Guidelines for prescribing anticoagulants in atrial fibrillation should balance treatment benefits and harms. Singer and colleagues calculated 6-year ischemic stroke rates (benefit) and intracrania... Background: Guidelines recommend warfarin use in patients with atrial fibrillation solely on the basis of risk for ischemic stroke without antithrombotic therapy. These guidelines rely on ischemic ...


  • Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atrial Fibrillation?

    by Daniel E. Singer, Yuchiao Chang, Margaret C. Fang, Leila H. Borowsky, Niela K. Pomernacki, Natalia Udaltsova, Alan S. Go

    Background— Randomized trials and observational studies support using an international normalized ratio (INR) target of 2.0 to 3.0 for preventing ischemic stroke in atrial fibrillation. We assessed whether the INR target should be adjusted based on selected patient characteristics. Methods and Results— We conducted a case–control study nested within the ATRIA cohort’s 9217 atrial fibrillation patients taking warfarin to define the relationship between INR level and the odds of thromboembolism (TE; mainly stroke) and of intracranial hemorrhage (ICH) relative to INR 2.0 to 2.5. We identified 396 TE cases and 164 ICH cases during follow-up. Each case was compared with 4 randomly selected controls matched on calendar date and stroke risk factors using matched univariable analyses and conditional logistic regression. We explored modification of the INR–outcome relationships by the following stroke risk factors: prior stroke, age, and CHADS 2 risk score. Overall, the odds of TE were low and stable above INR 1.8. Compared with INR 2.0 to 2.5, the relative odds of TE increased strikingly at INR 3.5 (eg, odds ratio, 3.56; 95% CI: 1.70 to 7.46, at INR 3.6 to 4.5). The relative odds of ICH were consistently low at INR 2 risk score. Conclusions— Our results confirm that the current standard of INR 2.0 to 3.0 for atrial fibrillation falls in the optimal INR range. Our findings do not support adjustment of INR targets according to previously defined stroke risk factors.